MOLBIO · NSE
Molbio Diagnostics Limited
₹1,495.5
-2.02% (-₹30.9)
Prev. close
₹1,526.4
Volume
7,00,865
Delivery %
18.5%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Molbio Diagnostic with a target of ₹1,650, a 29% upside, supported by a growing diagnostics market and expand…” | Mahesh M OjhaKantilal Chaganlal Securities | Molbio Diagnostics Ltd | PENDING |
Fundamentals
About Molbio Diagnostics Limited
Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and GI disorders. In addition, the company offers Truenat, a multi-disease real-time polymerase chain reaction platform that enables treatment decisions for various infectious and non-communicable diseases, such as tuberculosis, human immunodeficiency virus, malaria, viral hepatitis, COVID-19, dengue, chikungunya, influenza, H1N1, HPV/cervical cancer, cholera, leprosy, etc.; and Truenat assays. The company was incorporated in 2000 and is based in Verna, India.
Details
Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Sriram Natarajan
Headquarters
Verna
Employees
1,225
Website
molbiodiagnostics.comExchange
View on NSE ↗Key stats
Market cap
₹15,923.86 Cr
P/E ratio (TTM)
95.6
Dividend yield
0.00%
EPS (TTM)
₹14.46
Shares float
88.57 L
EPS · quarter ended Jun 2026
₹5.10
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹322.43 Cr | ₹819.73 Cr | ₹997.48 Cr | ₹1,414.96 Cr | |
EBITDA | ₹47.91 Cr | ₹184.34 Cr | ₹254.99 Cr | ₹326.17 Cr |
| ₹-72.60 L | ₹101.95 Cr | ₹145.10 Cr | ₹166.59 Cr | |
Diluted EPS | ₹-0.06 | ₹8.85 | ₹12.59 | ₹14.46 |
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹1,034.21 Cr | ₹1,221.06 Cr | ₹1,461.56 Cr | ₹2,148.42 Cr | |
| ₹118.54 Cr | ₹183.63 Cr | ₹146.93 Cr | ₹450.08 Cr | |
Stockholders' equity | ₹721.48 Cr | ₹823.38 Cr | ₹968.39 Cr | ₹1,169.34 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹64.13 Cr | ₹9.57 Cr | ₹287.10 Cr | ₹50.39 Cr | |
Investing cash flow | ₹-39.73 Cr | ₹-45.01 Cr | ₹-122.65 Cr | ₹-93.22 Cr |
| ₹18.24 Cr | ₹-31.55 Cr | ₹-26.15 Cr | ₹276.07 Cr | |
Capital expenditure | ₹-14.50 Cr | ₹-16.11 Cr | ₹-54.66 Cr | ₹-50.02 Cr |
End cash position | ₹-8.08 Cr | ₹-75.07 Cr | ₹63.23 Cr | ₹335.77 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Aug 26 |
|---|---|
| Promoter | 41.29% |
| Public | 58.71% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Molbio Diagnostics Limited | ₹15,566.62 Cr | ₹1,350.8 | 93.4 | 13.31 | 14.2% | 0.38 | +41.9% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Apollo Hospitals, Aster or Molbio — which is a better bet as healthcare stocks rally up to 4% despite D-Street weakness?
Livemint · 3 days ago
Molbio Diagnostics (NSE:MOLBIO) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Molbio Diagnostics reported FY ending September 2026 profit of ₹1.54 billion while generating ₹4.0 billion free cash flow, resulting in a negative accrual ratio of –0.19 that suggests cash generation exceeds reported earnings. The strong cash position and rising EPS have not yet moved the share price, highlighting a disconnect between the earnings release and market reaction.